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Abstract Background Patients, physicians and pharma-
cists are key stakeholders in the implementation of generic
substitution policies. Objectives To explore Lebanese
patients’ perceptions and experience, and pharmacists’
dispensing patterns towards the newly enacted unified
health prescription policy promoting generic substitution.
Setting Pharmacies in Beirut, the capital of Lebanon.
Methods A cross-sectional design employing self-admin-
istered questionnaires to survey a total of 128 patients and
25 pharmacists. Chi square test and multiple logistic
regression were performed. Main outcome Perceptions and
behaviors of patients and pharmacists towards the unified
health prescription and generic substitution. Results
Fourty-eight percent of the patients knew the definition of
generic drugs, among which 59.0% perceived that generic
drugs have the same effectiveness as their branded alter-
natives and 59.0% perceiving that generic drugs could
reduce Lebanon’s medical bill as well. Sixty-one percent of
the patients were aware of the unified health prescription.
Only 13.6% of the pharmacists suggested to patients to
replace prescribed brand drug by a generic when their
prescriptions were not marked with non-substitution.
Conclusions Progress has been made with regards to
enhancing generic substitution in the Lebanese healthcare
field. However, it remains important to educate patients
about generic medicines and plan context-specific schemes
that promote prescribing and dispensing of generic drugs
among physicians and pharmacists.
Keywords Access to medicine  Generic drugs  Health
policy  Lebanon  Outpatients  Pharmacy
Impact on practice
• Effective implementation of health policies that support
generic drug substitution is dependent on engagement
and better understanding of the perception of key
stakeholders including patients, pharmacists, and
physicians.
• Given their influence on patients perception, physicians
should play a leading role in patients education on the
financial benefits of using lower-priced generic drugs.
• Obstacles hindering pharmacists from recommending
generic substitution to patients should be further
investigated and addressed at a policy level.
Introduction
Ensuring the patients’ prompt and convenient access to
effective and reasonably-priced medications is a pivotal
component of all healthcare systems [1]. Nevertheless, the
healthcare systems of several countries are facing high
economic burden imposed by the increasing pharmaceuti-
cal expenses [1–5]. This has urged governments to consider
initiatives that aim to minimize these expenditures such as
generic drug substitution [6–11].
Generic substitution is based on offering patients a
therapeutically equivalent drug in terms of active
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substance, dosage form, and stability similar to its corre-
sponding brand name [12]. Generic drugs are generally
20–80% less expensive than brand alternatives [13, 14].
Thus, initiatives promoting their use ultimately serve as
long-term regulations of the healthcare expenditures allo-
cated to pharmaceuticals [13, 14].
The policy of generic drugs was introduced as a process
aiming to decrease the growing rate of pharmaceutical
expenditures [11, 15]. The policy consisting of replacing
prescribed brand drugs with their generic alternatives was
well illustrated in several countries such as Finland, Swe-
den, Norway and Japan [2, 4, 5, 16].
In the Eastern Mediterranean Region, a remarkable rise
in pharmaceutical expenditures has been recorded due to
the lack of adequate regulations. Lebanon was no exception
with the average percentage of Gross domestic product
(GDP) spent on pharmaceuticals’ sales exceeding that of
the countries of the Organisation for Economic Co-opera-
tion and Development (OECD) by 1.6%, and a per-capita
expenditure on pharmaceuticals increasing from US $249.7
in 2009 to approximately US $300 in 2012 [17]. Accord-
ingly, Lebanese health policy makers collaborated in 2011
on drafting the law of unified health prescription (UHP)
which focused on promoting generic drug substitution [18];
it was finally adopted in June 2015, under the Article
number 557 [19]. The adoption of the UHP law granted the
physician the ability to choose between two options when
prescribing a medication for the patient: (1) to mark the
UHP with the non-substitution (NS) abbreviation meaning
that substitution is highly not recommended and the use of
the brand drug is highly necessary, or (2) to leave the
corresponding box empty signaling to the pharmacist the
ability to dispense suitable generic drugs.
The success of the UHP is highly dependent on three
main stakeholders involved in the process: patients,
physicians and pharmacists. Patient readiness and pre-
paredness to receive an alternative generic medication is a
fundamental prerequisite that facilitates the uptake of
generics in the market [6, 16]. In contrast, tangible hesitant
behavior in this regards often stems from patients’ low
awareness about generics efficacy and benefits [20]. In this
context, physicians and pharmacists play a key role in
influencing patients’ beliefs and behavior [20, 21], and
enhancing informed decision making through the provision
of adequate information to patients regarding similarities
and equivalence between generic and brand drugs [22].
Despite the critical role that both pharmacists and patients
play in enhancing the effectiveness of the UHP law in
Lebanon, their level of understanding and acceptance of
generic drug substitution and unified prescriptions remain
unexplored at the local level, after effective passage of the
UHP policy.
Aim of the study
The purpose of this study was to examine the knowledge,
perceptions, and attitudes of patients and pharmacists vis-a`-
vis the adoption of the UHP policy in Lebanon, focusing
particularly on the generic drug substitution component of
the law.
Ethics approval
This study was conducted upon the approval of the
American University of Beirut’s Institutional Review
Board (FHS.SS.17). Informed consent was obtained from
the subjects prior to their participation in the study based
on a voluntarily basis.
Method
Study design
This study utilized a cross-sectional design to determine
the perceptions and attitudes of patients and pharmacists
towards the UHP law generally and the generic drug sub-
stitution specifically. The study assessed the patients’
readiness to use generic drugs as well. The survey instru-
ment was tested for face and content validity during a
2-week pilot period to insure an adequate sequence of
questions before circulating it to the target population.
The questionnaires were designed in Arabic considering
that individuals of the target population were Lebanese
native Arabic speakers. Two versions of a self-adminis-
tered questionnaire were developed. The patients’ ques-
tionnaire consisted of 11 questions including
demographics, general questions aiming to explore the
patient’s views on potential consequences of the use of
generics, and other questions addressing the health cover-
age status of the patients and their acceptance of generic
drugs’ utilization. The pharmacists’’ questionnaire con-
sisted of 4 questions including the proportion of prescribed
branded drugs that can be substituted, the extent to which
these prescriptions were labeled withNS and the pharma-
cist’s dispensing patterns. 5-point Likert scale was used for
questions addressing knowledge about generic drugs
(‘‘Strongly agree/Agree/Neutral/Disagree/Strongly dis-
agree’’). The percentage of the participants choosing each
of the five categories was then computed and presented in
three major classifications ‘‘Agree/Neutral/Disagree’’ for
data analysis purposes.
The target population was divided into two subgroups:
(1) pharmacists practicing in the Beirut District area, and
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(2) patients shopping at selected pharmacies located in the
city. Participants included in this study were males and
females aged above 18 years old. The survey was con-
ducted at 25 pharmacies, representing a proportion of
11.5% of the total pharmacies located in the city of Beirut.
The included pharmacies were randomly selected using
computer-generated numbers, and pharmacist’s refusal to
participate was accounted for by the identification of a
randomly selected replacement. The study included a total
of 153 respondents: 128 patients and 25 pharmacists. Each
pharmacy was visited once for 2 hours at a fixed pre-de-
fined scheduled time. The questionnaire was not self-ad-
ministered in cases where illiterate patients disclosed
interest in participating in the study; surveyors were trained
to assist these patients through orally addressing the
questions. This strategy was employed to minimize any
potential discrimination in the inclusion of patients and to
increase the response rate.
Statistical analysis
All the variables studied are categorical and reported as
proportions. Chi square Test was performed to determine
the association between independent variables and the
main outcomes; Fisher-exact test was similarly employed.
Multiple logistic regression analysis was used to identify
characteristics related to the knowledge of the definition of
generic drugs and to the awareness about UHP; the inde-
pendent variables were age, level of education, coverage by
a health insurance and the type of health insurance (if
existent). Perceptions of participants regarding the effec-
tiveness of generic drugs and their potential consequences
on the Lebanese medical bill were stratified by age, edu-
cational level and presence of health insurance. Dichot-
omized variables were used to study the proportion of UHP
labeled with NS, the proportion of physicians’ verbal rec-
ommendation of NS as well as the pharmacists’ sugges-
tions of substitution. The odds ratios (OR) were calculated
at 95% confidence intervals. Statistical analyses were
performed using SPSS version 20.0.
Results
The survey was conducted from March 2016 to April 2016
in 25 pharmacies in the Lebanese capital city, Beirut. The
final sample was 25 pharmacists and 128 patients,
excluding incomplete questionnaires.
Patients’ knowledge of generic drugs
The results show that 61 respondents (47.7%) knew the
definition of generic drugs (Table 1). A significant
difference between age groups was recorded in regards to
the knowledge about generics whereby respondents aged
between 18 and 35 years and those aged between 36 and
55 years, were five times (OR 4.945, p = 0.006) and eight
times (OR 7.709, p\ 0.001) more likely to know the
definition of generics compared to those aged above
55 years; respectively (Table 2). Findings also indicated a
significant association between the knowledge of the defi-
nition of generics and the level of education of the patients,
where 66.7% of the respondents with a graduate or post-
graduate degree were conscious about the definition of
generics compared to only 18.2% among those with pri-
mary education (p = 0.004) (Table 1). As for the health
insurance status, it was significantly associated with
knowledge about generics, whereby 54% of insured
respondents were aware of the generic drugs compared to
only 25% of their uninsured counterparts (p = 0.007)
(Table 1). Participants with private insurance were
approximately 4 times (OR 3.75) more likely to know
about generic drugs compared to the uninsured participants
(Table 2).
Patients’ awareness about UHP
Regarding the awareness about UHP among participants,
out of 128 participating patients, 78 (60.9%) were aware of
UHP (Table 1). Participants aged between 36 and 55 years
were 4.5 times (OR 4.473) more likely to be informed
about UHP compared to those aged 55 years and above
(p = 0.017) (Table 2). The awareness of UHP was corre-
lated with the educational level whereas only 38.1% of the
respondents with primary schooling were aware of the
concept of UHP compared to 80% of those with a graduate
or post-graduate degree (p = 0.007) (Table 1). In regards
to health insurance status, 69% of covered respondents
were aware of UHP in comparison to only 32.1% of
uninsured participants (p\ 0.001) (Table 1). Participants
covered by private insurance were almost five times (OR
5.344) more likely to be aware about the UHP compared to
their uninsured counterparts (p = 0.003). Similarly,
respondents covered by NSSF, military schemes or other
types of health insurance were four times (OR 3.947) more
likely to know about UHP compared to the uninsured
participants (p = 0.007) (Table 2).
Patients’ perceptions of the effectiveness
and benefits of generic drugs
Forty-two percent of participants agreed that generics are
as effective as their brand alternative and 45% perceived
that the use of generics could reduce Lebanon’s medical
bill (Table 3). More precisely, among the 61 participants
who knew the definition of generic drugs (Table 1), 59.0%
Int J Clin Pharm (2017) 39:1101–1109 1103
123
perceived that generics have the same effectiveness as their
brand alternatives, with the same proportion of 59.0%
perceiving that generic drugs could reduce Lebanon’s
medical bill as well (Table 4).
Patients’ experience with UHP
Among participating patients, 55.5% stated not having
their most recent prescription marked with NS, among
whom 16.9% reported that their physician verbally rec-
ommended NS without marking it on UHP form. It was
also found that in cases where UHP was not marked with
NS nor the physician recommended it verbally during the
consultation, 86.4% of pharmacists did not offer patients to
replace prescribed brand drug by its generic alternative.
Findings also showed that 25% of patients had no idea
about the NS constituent of UHP nor whether their
physician had marked NS or not, which accentuates
patients’ poor experience with UHP as a whole (Fig. 1).
Pharmacists’ dispensing patterns of generic drugs
Based on pharmacists’ surveys, 60% of UHPs received
from patients with brand drugs prescription were appro-
priate for generic drugs substitution. Among these, 70%
were initially marked with NS by the physician, which
prevented pharmacists from providing patients with alter-
native generic. For the 30% of UHP brand drug
Table 1 Respondents’ knowledge about generic drugs and unified health prescription
N (%) Knows the definition of generic drug N (%) Aware of unified health prescription N (%)
Yes No Yes No
Age groups
18–25 32 (25.0) 16 (50.0) 16 (50.0) 18 (56.2) 14 (43.8)
26–35 17 (13.3) 10 (58.8) 7 (41.2) 11 (64.7) 6 (35.3)
36–45 23 (18.0) 14 (60.9) 9 (39.1) 19 (82.6) 4 (17.4)
46–55 25 (19.5) 16 (64.0) 9 (36.0) 17 (68.0) 8 (32.0)
[55 31 (24.2) 5 (16.1) 26 (83.9) 13 (41.9) 18 (58.1)
Total 128 (100) 61 (47.7) 67 (52.3) 78 (60.9) 50 (39.1)
p = 0.002 p = 0.038
Level of education
Primary education 22 (17.2) 4 (18.2) 18 (81.8) 7 (31.8) 15 (68.2)
High school education 35 (27.3) 14 (40.0) 21 (60.0) 20 (57.1) 15(42.9)
Bachelor’s degree education 56 (43.8) 33 (58.9) 23 (41.1) 39 (69.6) 17 (30.4)
Graduate and post-graduate 15 (11.7) 10 (66.7) 5 (33.3) 12 (80.0) 3 (20.0)
Total 128 (100) 61 (47.7) 67 (52.3) 78 (60.9) 50 (39.1)
p = 0.004 p = 0.007
Health insurance
Insured 100 (78.1) 54 (54.0) 46 (46.0) 69 (69.0) 31 (31.0)
Uninsured 28 (21.9) 7 (25.0) 21 (75.0) 9 (32.1) 19 (67.9)
Total 128 (100) 61 (47.7) 67 (52.3) 78 (60.9) 50 (39.1)
p = 0.007 p\ 0.001
Type of health insurance
Military schemes 11 (11.0) 3 (27.3) 8 (72.7) 6 (54.4) 5 (45.5)
Private insurance 41 (41.0) 25 (61.0) 16 (39.0) 30 (73.2) 11 (26.8)
NSSFa 42 (42.0) 21 (50.0) 21 (50.0) 28 (66.7) 14 (33.3)
Otherb 6 (6.0) 5 (83.3) 1 (16.7) 5 (83.3) 1 (16.7)
Total 100 (100) 54 (54.0) 46 (46.0) 69 (69.0) 31 (31.0)
p = 0.097 p = 0.554
If p value B0.05, then the corresponding results are significant
a NSSF, the National Social Security Fund
b Other, covered by the Ministry of Public Health [18], Civil Servants Cooperative, Ministry of Social Affairs, Mutual Funds or Mutual Societies
and Self-Funded Schemes
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prescriptions unmarked with NS, 52% of pharmacists
suggested generic substitution to patients, while 53.8% of
patients revealed their preparedness to try generic drugs
(Fig. 2).
Discussion
According to our study, less than half of surveyed indi-
viduals (47.7%) knew the definition of generics compared
to 68.4% of the Japanese population [5]. Nevertheless, our
results are in alignment with the same Japanese study
reporting significant correlation between age and knowl-
edge about the definition of generics with oldest age groups
being less likely to know the definition of generics com-
pared to the younger ones [5].
While our study highlighted that more than half (59.0%)
of patients who knew the definition of generics perceived
that generics have the same effectiveness as their brand
alternatives, an even higher percentage was noted in Japan
(71.1%) [5]. Similar to the findings of a Portuguese study,
our study showed that younger and more educated indi-
viduals were more aware of UHP and generics compared to
their older and less educated counterparts [22].
With regards to the perception of the ability of generics
to reduce the national medical bill, only 45.0% of our
respondents perceived that ability of generics, compared to
almost a double of this proportion (86.0%) among Japanese
population [5]. This strongly highlights the fact that
Lebanese population still has a weak appreciation of lower
prices of generics compared to brand drugs. In fact, weak
comprehension of the financial benefits of using lower-
priced generics leads to low levels of patients’ acceptance
and willingness to actually purchase these drugs instead of
brand alternatives [4]. This underlines the need to address
the Lebanese perception of the ability of generics to reduce
the per-capita expenditure on pharmaceuticals as a mean to
enhance their willingness to use generic substitution.
Generally, exploring the understanding and attitudes of
patients towards the UHP policy and generic substitution
are fundamental to achieving successful implementation of
the policy. This study reported a much higher rate of pre-
paredness to try generics among Lebanese patients (53.8%)
than that among the Iranians (19%) [21]. This study further
highlighted the tendency of physicians to prescribe or
verbally recommend brand drugs instead of generics, and
that of pharmacists to dispense brand drugs instead of their
generic alternatives. These patterns were mirrored by the
low rate of patients’ acceptance and readiness to use
generics (53.8%). These findings concur with similar
results reported in other studies in literature
[4, 5, 16, 23–27].
Reflecting on Lebanese physicians’ prescription patterns
in the context of the Middle East and North Africa
Table 2 Logistic regression showing factors associated with knowledge of the definition of generic drug and awareness of Unified Health
Prescription
Knows the definition of generic drug Aware of unified health prescription
OR 95% CI p value OR 95% CI p value
Age groups
18–35 4.945a (1.59–15.382) 0.006 1.469 (0.555–3.889) 0.438
36–55 7.709a (2.456–24.204) \0.001 3.473a (1.252–9.633) 0.017
55 and aboveb 1.00 1.00
Health insurance groups
Private insurance 3.754a (1.209–11.652) 0.022 5.344a (1.783–16.019) 0.003
NSSF/military schemes/others 2.352 (0.811–6.824) 0.115 3.947a (1.446–10.777) 0.007
Not insuredb 1.00 1.00
CI, confidence interval; OR, odds ratios reflecting the likelihood of the knowledge of the definition of generic drugs and of the awareness of the
unified health prescription
a Indicates significance at p value B0.05
b Reference group
Table 3 Respondents’ perceptions about the effectiveness and cost-
related benefits of generic drugs
Total sample Agree Neutral Disagree
Generic drug is as effective as brand drug N (%)
112a 47 (42.0) 43 (38.4) 22 (19.6)
Generic drug can reduce the country’s medical bill N (%)
111b 50 (45.0) 45 (40.5) 16 (14.4)
a Total sample is 112 instead of 128 because of missing data
b Total sample is 111 instead of 128 because of missing data
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(MENA) region, our study detected that 60% of prescrip-
tions of brand drugs could be substituted by generic
alternatives, indicating a low rate of generic prescriptions
by Lebanese physicians. This finding was further empha-
sized by Hamadeh et al., who stated that generics account
only for 2.9% of total medication prescriptions in Lebanon
[28], similar to results of other studies conducted in the
region including Dubai, (4.4%) [29], Sudan (19.5%) [21],
and Saudi Arabia (15.1%) [30]. These regional figures dif-
fer considerably from findings reported in Finland and
Italy, characterized by low opposition of physicians to
generic substitution [4, 7].
Focusing on figures specific to pharmacists, our study
demonstrated, a notably low rate of generic recommenda-
tion (13.6%) to patients by pharmacists in cases where
UHP was unmarked with NS nor physicians recommended
verbally the use of generics. This is in contrary to Aus-
tralian pharmacists who were found to frequently suggest
generic substitutions [31], and practices in New Jersey
where generic substitution accounted for 96% of dispensed
drugs [27]. Thus, it is pivotal to investigate and understand
potential reasons leading to pharmacists’ lack of enthusi-
asm to recommend generic substitution and actually dis-
pense it. A study from Japan revealed several obstacles that
might hinder pharmacists from recommending generic
substitution [5], such as a smaller margin of profit in cases
of generic substitution, unavailability of the appropriate
generic drug in the pharmacy specifically or the market
Table 4 Perceptions of respondents knowledgeable about generic drugs on its effectiveness compared to brand alternatives and its ability to
reduce the country’s medical bill
Generic drug is as effective as brand drug N (%) Generic drug can reduce the country’s medical bill N (%)
Agree Neutral Disagree Agree Neutral Disagree
Age (years)
18–45 28 (77.8) 5 (55.6) 7 (43.8) 27 (75.0) 6 (60.0) 7 (46.7)
46 and above 8 (22.2) 4 (44.4) 9 (56.3) 9 (95.0) 4 (40.0) 8 (53.3)
p = 0.046 p = 0.14
Level of education
Primary/high school 11 (30.6) 3 (33.3) 4 (25.0) 8 (22.0) 7 (70.0) 3 (20.0)
Bachelor’s/graduate degree 25 (69.4) 6 (66.7) 12 (75.0) 28 (78.0) 3 (30.0) 12 (80.0)
p = 0.888 p = 0.014
Health insurance
Yes 32 (88.5) 8 (88.9) 14 (87.5) 33 (91.7) 7 (70.0) 14 (93.3)
No 4 (11.1) 1 (11.1) 2 (12.5) 3 (8.3) 3 (30.0) 1 (6.7)
p = 0.989 p = 0.153
Total 36 (59.0) 9 (14.8) 16 (26.2) 36 (59.0) 10 (16.4) 15 (24.6)
If p value B0.05, then the corresponding results are significant
Fisher-exact test was used
Physician's prescription marked with 'NS' 
Yes 
25 (19.5%)
No
71 (55.5%)
Physician verbally recommended 'NS'
Yes
12 (16.9%)
No
59 (83.1%)
Pharmacist recommended substitution
Yes
8 (13.6%)
No
51 (86.4%)
Do not know
32 (25%)
Fig. 1 Patterns of prescribing and dispensing generic drugs based on
patients’ experience
1106 Int J Clin Pharm (2017) 39:1101–1109
123
generally, or perception of low quality of generics [5].
These obstacles could also apply to the Lebanese phar-
maceutical market and represent potential hypotheses for
reasons behind the figures obtained in our study.
Despite the fact that the new UHP law has officially
been put into effect in Lebanon, patients’ knowledge and
attitudes on one hand, and health professionals’ practices
on the other hand, may be imposing a challenge for its
adequate and effective implementation. It remains crucial
to plan and invest in targeted approaches tailored based on
the findings corresponding to each of the physicians,
pharmacists, and patients. Examples of strategies that could
be used to address patients were thoroughly presented in
literature [25]. As for physicians, training and informative
programs, recommended to start as early as medical edu-
cation, should address foundations of adequate prescription
patterns besides the quality and safety of generics in the
market.
As for pharmacists, further investigation is required to
identify reasons leading to the observed dispensing
behaviors. Given that pharmacists have identified lack of
incentives to substitute brand drugs with generics, efforts
should be invested in designing effective incentive
schemes to enhance generic substitution among pharma-
cists. From a financial lens, Lebanese pharmacists would
rather not advocate for cheaper generics, as these are per-
ceived to limit their profitability. In fact, this notion is
shared with pharmacists in New Zealand, who believe that
generic drugs impact their profitability for several reasons
including the urge to increase the volume of sales to
compensate for the decreased profit resulting from substi-
tution which necessitates extensive inventory planning
[32]. Moreover, explaining the idea of generics to patients
is considered time consuming and generics’ recommenda-
tion may alter the patient–pharmacist relationship in case
any corresponding undesirable side effect arises [32].
Findings of this study were congruent with those of a
systematic review reporting that 33.4 and 17.6% of phar-
macists believed that generics were of lower quality, and
result in more side effects than brand alternatives; respec-
tively [33].
Limitations
A number of limitations in this study are worth mentioning.
First, the study did not secure a larger number of respon-
dents, questioning its representation of all Lebanese phar-
macists and patients. Moreover, restricting participants’
selection to the city of Beirut solely may have masked
potential differences that would have emerged if the study
were to be conducted in several other regions. Also, the
generalizability may have been impacted by the under-
representation of the uninsured patients compared to their
insured counterparts. As for the study design, it may have
favored social desirability bias, where pharmacists might
have overestimated the number of NS marked prescriptions
in order to shift the liability to physicians.
Although we succeeded to interview 128 participants, it
remains very probable to have missed valuable input from
other participants that were not captured at pharmacies
during data collection. These include, for example, elderly
patients incapable of personally buying their medications
and employees who logistically couldn’t be captured due to
time conflict with their work schedule.
In terms of analysis, the factor of gender was not
included in the questionnaire, which consequently did not
allow testing for potential association between gender and
the observed results.
Despite the aforementioned limitations, this study pre-
sented pivotal baseline information providing insights into
60% of brand drugs prescriptions could be substituted with generic drugs
70% of prescriptions were marked with 'NS' 30% of prescritions were not marked with 'NS'
52% of pharmacists 
recommended substitution
53.8% of patients are willing to substitute 
brand drugs with generic drugs
46.2% of patients are not willing to to 
substitute brand drugs with generic 
drugs
48% of pharmacists did not 
recommend substitution
Fig. 2 An overview of pharmacists’ dispensing patterns
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Lebanese pharmacists’ behaviors and patients’ perceptions
towards UHP. Findings of this study, in fact, constitute a
cornerstone for effective targeted interventions that aim to
enhance the efficacious implementation of the UHP law in
Lebanon specifically, and in countries with similar profile
generally.
Conclusion
This study investigated Lebanese patients’ perceptions and
attitudes as well as prescribing and dispensing practices of
physicians and pharmacists in light of the new UHP policy
enacted in June 2015. The findings reveal that progress has
been made; nevertheless, it highlights the need to educate
patients on the use of generics and plan context-specific
schemes that aim to promote the prescription and dispense
of generics among physicians and pharmacists.
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